InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,031.17
(
-0.80%
)
US TECH 100
16,922.40
(
-0.81%
)
Dow Jones
38,002.36
(
-1.19%
)
Brent Oil
87.01
(
-0.25%
)
Bitcoin
64,512.70
(
0.36%
)
Post# of 251596
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119480
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Rocky3 post# 177478

Wednesday, 09/10/2014 10:10:41 AM

Wednesday, September 10, 2014 10:10:41 AM

Post# of 251596
GILD—We now know that Stifel was indeed out to lunch (as noted in #msg-101431769) when they projected that 90% of Solavdi + Ledipasvir patients would take the 8w regimen. According to John Milligan on the MS webcast yesterday, GILD expects 45% of patients will take the 8w regimen and 55% will take the 12w regimen.

Some sell-side analysts really don’t have a clue in the HCV arena.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up